Investigational GLP-1 Candidates: Stage & Sources
Development stage, trial identifiers and sources for amycretin (Novo Nordisk), VK2735 (Viking Therapeutics) and CagriSema (Novo Nordisk).
The candidates listed here are investigational, not FDA-approved. TrimSoMo lists only their development stage, trial identifiers and public sources.
Development stage, trial identifiers and sources for amycretin (Novo Nordisk), VK2735 (Viking Therapeutics) and CagriSema (Novo Nordisk).
Eli Lilly and Company. FDA approval: April 1, 2026.
FDA-approved use (from the FDA announcement): Foundayo is approved for use in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.
Foundayo's FDA labeling includes a boxed warning. Read the full prescribing information before making any decision.
Checked November 4, 2026. Read the FDA label and talk with a clinician for details.